Limits...
Antinociceptive Effects of Transcytosed Botulinum Neurotoxin Type A on Trigeminal Nociception in Rats.

Kim HJ, Lee GW, Kim MJ, Yang KY, Kim ST, Bae YC, Ahn DK - Korean J. Physiol. Pharmacol. (2015)

Bottom Line: Subcutaneous (3 U/kg) or intracisternal (0.3 or 1 U/kg) administration of BoNT-A significantly inhibited the formalin-induced nociceptive response in the second phase.These results suggest that the central antinociceptive effects the peripherally or centrally administered BoNT-A are mediated by transcytosed BoNT-A or direct inhibition of trigeminal neurons.Our data suggest that central targets of BoNT-A might provide a new therapeutic tool for the treatment of orofacial chronic pain conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Physiology, School of Dentistry, Kyungpook National University, Daegu 700-412, Korea.

ABSTRACT
We examined the effects of peripherally or centrally administered botulinum neurotoxin type A (BoNT-A) on orofacial inflammatory pain to evaluate the antinociceptive effect of BoNT-A and its underlying mechanisms. The experiments were carried out on male Sprague-Dawley rats. Subcutaneous (3 U/kg) or intracisternal (0.3 or 1 U/kg) administration of BoNT-A significantly inhibited the formalin-induced nociceptive response in the second phase. Both subcutaneous (1 or 3 U/kg) and intracisternal (0.3 or 1 U/kg) injection of BoNT-A increased the latency of head withdrawal response in the complete Freund's adjuvant (CFA)-treated rats. Intracisternal administration of N-methyl-D-aspartate (NMDA) evoked nociceptive behavior via the activation of trigeminal neurons, which was attenuated by the subcutaneous or intracisternal injection of BoNT-A. Intracisternal injection of NMDA up-regulated c-Fos expression in the trigeminal neurons of the medullary dorsal horn. Subcutaneous (3 U/kg) or intracisternal (1 U/kg) administration of BoNT-A significantly reduced the number of c-Fos immunoreactive neurons in the NMDA-treated rats. These results suggest that the central antinociceptive effects the peripherally or centrally administered BoNT-A are mediated by transcytosed BoNT-A or direct inhibition of trigeminal neurons. Our data suggest that central targets of BoNT-A might provide a new therapeutic tool for the treatment of orofacial chronic pain conditions.

No MeSH data available.


Related in: MedlinePlus

Effects of the subcutaneous (A) or intracisternal (B) injection of botulinum neurotoxin type A (BoNT-A) on the NMDA-induced nociceptive behavior. Intracisternal administration of 0.5 µg NMDA evoked a significant nociceptive behavior by the activation of trigeminal neurons. Both subcutaneous and intracisternal injections of BoNT-A attenuated the number of rubbing induced by the intracisternal injection of NMDA. *p<0.05 vehicle vs. BoNT-A treated group, n=8 animals per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499647&req=5

Figure 3: Effects of the subcutaneous (A) or intracisternal (B) injection of botulinum neurotoxin type A (BoNT-A) on the NMDA-induced nociceptive behavior. Intracisternal administration of 0.5 µg NMDA evoked a significant nociceptive behavior by the activation of trigeminal neurons. Both subcutaneous and intracisternal injections of BoNT-A attenuated the number of rubbing induced by the intracisternal injection of NMDA. *p<0.05 vehicle vs. BoNT-A treated group, n=8 animals per group.

Mentions: Fig. 3 illustrates the effects of BoNT-A on the nociceptive behavior induced by the intracisternal injection of NMDA. Intracisternal administration of 0.5 µg NMDA produced significant nociceptive behavior via the activation of trigeminal neurons. Subcutaneous injection of 1 or 3 U/kg BoNT-A attenuated the NMDA-induced nociceptive rubbing response (p<0.05, Fig. 3A). Then we examined the NMDA-induced nociceptive behavior after the intracisternal injection of BoNT-A. Intracisternal injection of 0.3 or 1 U/kg BoNT-A significantly reduced the number of rubbing induced by the intracisternal administration of NMDA (p<0.05, Fig. 3B).


Antinociceptive Effects of Transcytosed Botulinum Neurotoxin Type A on Trigeminal Nociception in Rats.

Kim HJ, Lee GW, Kim MJ, Yang KY, Kim ST, Bae YC, Ahn DK - Korean J. Physiol. Pharmacol. (2015)

Effects of the subcutaneous (A) or intracisternal (B) injection of botulinum neurotoxin type A (BoNT-A) on the NMDA-induced nociceptive behavior. Intracisternal administration of 0.5 µg NMDA evoked a significant nociceptive behavior by the activation of trigeminal neurons. Both subcutaneous and intracisternal injections of BoNT-A attenuated the number of rubbing induced by the intracisternal injection of NMDA. *p<0.05 vehicle vs. BoNT-A treated group, n=8 animals per group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499647&req=5

Figure 3: Effects of the subcutaneous (A) or intracisternal (B) injection of botulinum neurotoxin type A (BoNT-A) on the NMDA-induced nociceptive behavior. Intracisternal administration of 0.5 µg NMDA evoked a significant nociceptive behavior by the activation of trigeminal neurons. Both subcutaneous and intracisternal injections of BoNT-A attenuated the number of rubbing induced by the intracisternal injection of NMDA. *p<0.05 vehicle vs. BoNT-A treated group, n=8 animals per group.
Mentions: Fig. 3 illustrates the effects of BoNT-A on the nociceptive behavior induced by the intracisternal injection of NMDA. Intracisternal administration of 0.5 µg NMDA produced significant nociceptive behavior via the activation of trigeminal neurons. Subcutaneous injection of 1 or 3 U/kg BoNT-A attenuated the NMDA-induced nociceptive rubbing response (p<0.05, Fig. 3A). Then we examined the NMDA-induced nociceptive behavior after the intracisternal injection of BoNT-A. Intracisternal injection of 0.3 or 1 U/kg BoNT-A significantly reduced the number of rubbing induced by the intracisternal administration of NMDA (p<0.05, Fig. 3B).

Bottom Line: Subcutaneous (3 U/kg) or intracisternal (0.3 or 1 U/kg) administration of BoNT-A significantly inhibited the formalin-induced nociceptive response in the second phase.These results suggest that the central antinociceptive effects the peripherally or centrally administered BoNT-A are mediated by transcytosed BoNT-A or direct inhibition of trigeminal neurons.Our data suggest that central targets of BoNT-A might provide a new therapeutic tool for the treatment of orofacial chronic pain conditions.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Physiology, School of Dentistry, Kyungpook National University, Daegu 700-412, Korea.

ABSTRACT
We examined the effects of peripherally or centrally administered botulinum neurotoxin type A (BoNT-A) on orofacial inflammatory pain to evaluate the antinociceptive effect of BoNT-A and its underlying mechanisms. The experiments were carried out on male Sprague-Dawley rats. Subcutaneous (3 U/kg) or intracisternal (0.3 or 1 U/kg) administration of BoNT-A significantly inhibited the formalin-induced nociceptive response in the second phase. Both subcutaneous (1 or 3 U/kg) and intracisternal (0.3 or 1 U/kg) injection of BoNT-A increased the latency of head withdrawal response in the complete Freund's adjuvant (CFA)-treated rats. Intracisternal administration of N-methyl-D-aspartate (NMDA) evoked nociceptive behavior via the activation of trigeminal neurons, which was attenuated by the subcutaneous or intracisternal injection of BoNT-A. Intracisternal injection of NMDA up-regulated c-Fos expression in the trigeminal neurons of the medullary dorsal horn. Subcutaneous (3 U/kg) or intracisternal (1 U/kg) administration of BoNT-A significantly reduced the number of c-Fos immunoreactive neurons in the NMDA-treated rats. These results suggest that the central antinociceptive effects the peripherally or centrally administered BoNT-A are mediated by transcytosed BoNT-A or direct inhibition of trigeminal neurons. Our data suggest that central targets of BoNT-A might provide a new therapeutic tool for the treatment of orofacial chronic pain conditions.

No MeSH data available.


Related in: MedlinePlus